Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

Abstract

PURPOSE Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year period. MATERIALS AND METHODS In this double-blind, placebo controlled phase III study 646 men… (More)
DOI: 10.1016/j.juro.2010.06.022

4 Figures and Tables

Topics

  • Presentations referencing similar topics